Figure 4.

Overview of Main Inflammasome Treatment Options and Their Modes of Action

Currently, drugs targeting IL-1β signaling, ie, anakinra and canakinumab, and tubuli formation (colchicine) are the only treatment options in clinical trials for CVD (dark blue). There are, however, promising results from smaller preclinical studies using compounds more directly targeting the NLRP3 inflammasome (ie, 16673-34-0, MCC950, Bay-11-7082, tranilast) or caspase-1 (VX-765) (light blue). For more details on drugs targeting NLRP3, see the review by Mezzaroma et al (74).